高级检索
当前位置: 首页 > 详情页

miR-1972 inhibits hepatocellular carcinoma proliferation by targeting GZMH-mediated DNA replication in the cell cycle

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

机构: [1]First Peoples Hosp Yunnan Prov Kunming, Dept Hepatobiliary Surg, 157 Jinbi Rd, Kunming 650032, Yunnan, Peoples R China [2]First Peoples Hosp Yunnan Prov, Res Ctr Digital Med, 157 Jinbi Rd, Kunming 650032, Yunnan, Peoples R China [3]Kunming Univ Sci & Technol, Affiliated Hosp, Kunming 650032, Yunnan, Peoples R China
出处:
ISSN:

关键词: hepatocellular carcinoma miR-1972 GZMH cell cycle DNA replication proliferation

摘要:
Aim To understand the regulatory roles of miR-1972 and GZMH in hepatocellular carcinoma (HCC) and explore their potential as therapeutic biomarkers.Methods In vitro verification of the regulation of malignant cell behavior by differential expression of miR-1972 in HCC cells. The GSE113996 dataset was studied using weighted gene co-expression network analysis (WGCNA) and differential expressed genes respectively to identify the key prognostic gene GZMH and assess the effect of its differential expression on the prognosis of the patient. Finally, the regulation of GZMH expression by miR-1972 was verified, and the effect of their combination on HCC cell behavior was analyzed.Results Inhibition of miR-1972 can reduce cell proliferation, migration, and invasion, while overexpression of miR-1972 has the opposite effect in HCC cells. According to the data, a positive prognosis for HCC was linked with higher GZMH expression. Interestingly, miR-1972 was observed to reverse-regulate the expression of GZMH. Besides, the combined regulation of GZMH and miR-1972 has been discovered to affect the cell growth, invasive capacity, and migratory potential of HCC cells, especially the cell cycle arrest in the G2 phase.Conclusions miR-1972 regulates the malignant behavior of HCC cells, especially cell proliferation, by regulating GZMH expression.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2024]版:
最新[2023]版:
大类 | 4 区 医学
小类 | 4 区 药学
JCR分区:
出版当年[2023]版:
Q2 PHARMACOLOGY & PHARMACY
最新[2023]版:
Q2 PHARMACOLOGY & PHARMACY

影响因子: 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者:
第一作者机构: [1]First Peoples Hosp Yunnan Prov Kunming, Dept Hepatobiliary Surg, 157 Jinbi Rd, Kunming 650032, Yunnan, Peoples R China [3]Kunming Univ Sci & Technol, Affiliated Hosp, Kunming 650032, Yunnan, Peoples R China
共同第一作者:
通讯作者:
通讯机构: [1]First Peoples Hosp Yunnan Prov Kunming, Dept Hepatobiliary Surg, 157 Jinbi Rd, Kunming 650032, Yunnan, Peoples R China [2]First Peoples Hosp Yunnan Prov, Res Ctr Digital Med, 157 Jinbi Rd, Kunming 650032, Yunnan, Peoples R China [3]Kunming Univ Sci & Technol, Affiliated Hosp, Kunming 650032, Yunnan, Peoples R China [*1]Department of Hepatobiliary Surgery, The First People’s Hospital of Yunnan Province Kunming, No. 157, Jinbi Road, Xishan District, Kunming, Yunnan 650032, China [*2]Research Center of Digital Medicine, The First People’s Hospital of Yunnan Province, Kunming, No. 157, Jinbi Road, Xishan District, Kunming, Yunnan 650032, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:83045 今日访问量:0 总访问量:682 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 云南省第一人民医院 技术支持:重庆聚合科技有限公司 地址:云南省昆明市西山区金碧路157号